Hosts: Dr. Daniel Ennis, Dr. Janet Pope

Guest: Dr. Marinka Twilt (Pediatric Rheumatologist, University of Calgary; ASM Program Committee Chair)

We’re coming to you almost live from Halifax for Day 1 of the Canadian Rheumatology Association ASM. The day featured key updates across the field, including gaps in pediatric trials, growing recognition of autoinflammatory diseases, and the expanding role of genetics.

The SELECT-GCA trial reinforced that upadacitinib is effective for both induction and maintenance of Giant Cell Arteritis (GCA), with high relapse rates after stopping—supporting longer-term treatment. In pediatric ANCA vasculitis, rituximab showed similar efficacy to cyclophosphamide with a safer profile.

Sessions on “tough-to-treat RA” highlighted how often non-inflammatory factors drive symptoms, while Clinical Pearls and Medical Mysteries emphasized revisiting diagnoses and the importance of pathology and genetics.

The keynote by Dr. Elizabeth Volkman rounded out the day with a focus on holistic care and patient empowerment.

 Main Takeaways

• GCA likely requires longer-term therapy to prevent relapse
• Rituximab is a safe, effective alternative in pediatric ANCA vasculitis
• “Tough-to-treat RA” often reflects non-inflammatory disease
• Reassess when treatments fail—diagnosis evolves
• Genetics and pathology are increasingly central to complex cases
• Holistic care and patient empowerment matter for outcomes

What to Watch on Day 2

• New myositis insights, including statin-associated disease
• Podium presentations showcasing emerging research
• Hands-on workshops (including TMJ)
• Poster tours, with a focus on trainee work
• The Great Debate: “Be it resolved that medications should be tapered in patients with inflammatory arthritis in remission.”

More highlights coming tomorrow—stay tuned!